Executive summary Despite substantial progress in reducing the global impact of many non-
communicable diseases, including heart disease and cancer, morbidity and mortality due to …

Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published the
complete 2023 GOLD report, which can be freely downloaded from its web page (www …

Disclosures: Dr. Labaki, ACP Contributing Author, reports nonfinancial support from
Pulmonx and personal fees from Konica Minolta outside the submitted work. Dr. Rosenberg …

Heart Failure Society (JHFS). The working committee for this project includes members and
collaborators involved in the previous versions of the heart failure guidelines and members …

Cardiovascular diseases (CVDs) are arguably the most important comorbidities in chronic
obstructive pulmonary disease (COPD). CVDs are common in people with COPD, and their …

Chronic obstructive pulmonary disease (COPD) is a global health issue with high social and
economic costs. Concomitant chronic cardiac disorders are frequent in patients with COPD …

Disorders of lipid metabolism. Clinical Guidelines 2023 | Ezhov | Russian Journal of
Cardiology Russian Journal of Cardiology eng | рус User ISSN 1560-4071 (Print) ISSN …

При участии: Национального общества по изучению атеросклероза (НОА), Российской
ассоциации эндокринологов (РАЭ), Российского общества кардиосоматической …

Aims The aim of this study was to clarify the effect of β-blockers (BBs) on respiratory function
and survival in patients with chronic obstructive pulmonary disease with cardiovascular …